R
Ronald N. Marcus
Researcher at Bristol-Myers Squibb
Publications - 106
Citations - 8845
Ronald N. Marcus is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Aripiprazole & Placebo. The author has an hindex of 47, co-authored 106 publications receiving 8346 citations. Previous affiliations of Ronald N. Marcus include Ohio State University.
Papers
More filters
Journal ArticleDOI
Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder.
Randall Owen,Linmarie Sikich,Ronald N. Marcus,Patricia K. Corey-Lisle,George Manos,Robert D. McQuade,William H. Carson,Robert L. Findling +7 more
TL;DR: Aripiprazole demonstrated significantly greater global improvements than placebo, as assessed by the mean CGI-I score from week 1 through week 8; however, clinically significant residual symptoms may still persist for some patients.
Journal ArticleDOI
A Placebo-Controlled, Fixed-Dose Study of Aripiprazole in Children and Adolescents With Irritability Associated With Autistic Disorder
Ronald N. Marcus,Randall Owen,Lisa Kamen,George Manos,Robert D. McQuade,William H. Carson,Michael G. Aman +6 more
TL;DR: Aripiprazole was efficacious and generally safe and well tolerated in the treatment of children and adolescents with irritability associated with autistic disorder.
Journal ArticleDOI
Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.
Stephen R. Marder,Robert D. McQuade,Elyse Stock,Stephen Kaplita,Ronald N. Marcus,Allan Z. Safferman,A. Saha,Mirza Ali,Taro Iwamoto +8 more
TL;DR: Aripiprazole shows a favorable safety and tolerability profile with low potential for EPS, weight gain, prolactin elevation, QT(c) prolongation, and sedation and may offer benefits in schizophrenia treatment.
Journal ArticleDOI
A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania.
Paul E. Keck,Ronald N. Marcus,Stavros Tourkodimitris,Mirza Ali,Amy Liebeskind,A. Saha,Gary G. Ingenito +6 more
TL;DR: Aripiprazole had significantly greater efficacy than placebo for the treatment of bipolar disorder patients in acute manic or mixed episodes and was safe and well tolerated in this randomized controlled trial.
Journal ArticleDOI
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder : A multicenter, randomized, double-blind, placebo-controlled study
Robert M. Berman,Ronald N. Marcus,Rene Swanink,Robert D. McQuade,William H. Carson,Patricia K. Corey-Lisle,Arif Ullah Khan +6 more
TL;DR: In patients with MDD who showed an incomplete response to ADT, adjunctive aripiprazole was efficacious and well tolerated.